SG10201902326XA - Mk2 inhibitors and uses thereof - Google Patents
Mk2 inhibitors and uses thereofInfo
- Publication number
- SG10201902326XA SG10201902326XA SG10201902326XA SG10201902326XA SG10201902326XA SG 10201902326X A SG10201902326X A SG 10201902326XA SG 10201902326X A SG10201902326X A SG 10201902326XA SG 10201902326X A SG10201902326X A SG 10201902326XA SG 10201902326X A SG10201902326X A SG 10201902326XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- compositions
- available
- methods
- same
- Prior art date
Links
- 229940124789 MK2 inhibitor Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
MK2 INHIBITORS AND USES THEREOF The present invention provides compounds, compositions thereof, and methods of using the same. [No available figure]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051788P | 2014-09-17 | 2014-09-17 | |
| US201562199927P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201902326XA true SG10201902326XA (en) | 2019-04-29 |
Family
ID=55454109
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201902326XA SG10201902326XA (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
| SG11201701861RA SG11201701861RA (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701861RA SG11201701861RA (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9458175B2 (en) |
| EP (2) | EP3193611B1 (en) |
| JP (3) | JP6556225B2 (en) |
| KR (1) | KR102457848B1 (en) |
| CN (1) | CN106998692B (en) |
| AU (1) | AU2015317741B2 (en) |
| BR (1) | BR112017005266B1 (en) |
| CA (1) | CA2961607C (en) |
| CL (1) | CL2017000576A1 (en) |
| CO (1) | CO2017003279A2 (en) |
| CY (1) | CY1124215T1 (en) |
| DK (1) | DK3193611T3 (en) |
| EA (1) | EA037299B1 (en) |
| EC (1) | ECSP17023281A (en) |
| ES (1) | ES2874561T3 (en) |
| HR (1) | HRP20210529T1 (en) |
| HU (1) | HUE054347T2 (en) |
| IL (1) | IL251051B (en) |
| LT (1) | LT3193611T (en) |
| MA (1) | MA40534B1 (en) |
| MX (2) | MX373341B (en) |
| PL (1) | PL3193611T3 (en) |
| PT (1) | PT3193611T (en) |
| RS (1) | RS62017B1 (en) |
| SA (1) | SA517381115B1 (en) |
| SG (2) | SG10201902326XA (en) |
| SI (1) | SI3193611T1 (en) |
| SM (1) | SMT202100311T1 (en) |
| TW (1) | TWI744217B (en) |
| WO (1) | WO2016044463A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| RS62017B1 (en) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| CN106632077B (en) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | A kind of preparation method of 2- amino -4- Bromopyrimidine |
| JP2020514361A (en) * | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | 9,10,11,12-Tetrahydro-8H- [1,4] diazepino [5 ', 6': 4,5] thieno [3,2-F] quinolin-8-one compounds and uses thereof |
| WO2018170200A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| US10882867B2 (en) * | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| WO2018170201A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Deuterated analogs of mk2 inhibitors and uses thereof |
| CN107058259A (en) * | 2017-05-18 | 2017-08-18 | 南京中医药大学 | Molecular marker MK2 genes and its application |
| CN112996529A (en) * | 2018-10-02 | 2021-06-18 | 迪斯克医药公司 | Matriptase 2 inhibitor and application thereof |
| EP3969456A4 (en) * | 2019-05-17 | 2023-01-25 | Celgene CAR LLC | Methods of treating a mk2-mediated disorder |
| CA3171335A1 (en) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Mono and combination therapies with ulk1/2 inhibitors |
| WO2021178449A1 (en) * | 2020-03-02 | 2021-09-10 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| WO2022020562A1 (en) * | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| US20230414575A1 (en) * | 2020-11-12 | 2023-12-28 | Akttyva Therapeutics, Inc. | Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders |
| US12049470B2 (en) | 2021-02-01 | 2024-07-30 | Celgene Corporation | MK2 inhibitors, the synthesis thereof, and intermediates thereto |
| EP4079855A1 (en) * | 2021-04-20 | 2022-10-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Compound and method for the prophylaxis and treatment of leukemia |
| WO2023025298A1 (en) * | 2021-08-27 | 2023-03-02 | 瑞石生物医药有限公司 | Quinolinofuran derivative and use thereof |
| KR20240134978A (en) | 2022-01-14 | 2024-09-10 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | Pyridine-containing polycyclic derivatives, preparation method thereof and use thereof |
| WO2024044731A1 (en) * | 2022-08-26 | 2024-02-29 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| TW202432106A (en) * | 2022-10-27 | 2024-08-16 | 美商必治妥美雅史谷比公司 | Mk2 inhibitors and uses thereof |
| WO2024167950A1 (en) * | 2023-02-07 | 2024-08-15 | Celgene Corporation | Compounds and compositions useful as degraders of mk2 kinase |
| WO2024229401A2 (en) * | 2023-05-04 | 2024-11-07 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| WO2025002076A1 (en) * | 2023-06-26 | 2025-01-02 | 深圳信立泰药业股份有限公司 | Uses of mk2 inhibitor in the preparation of drugs for preventing and/or treating diseases |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015778A (en) | 1989-12-18 | 1991-05-14 | The Dow Chemical Company | Catalytic method to produce hydroxy substituted arylophenones |
| CN1087725C (en) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | Enhancement of the effect of drugs by deuteration |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| KR20050104339A (en) | 2002-12-20 | 2005-11-02 | 파마시아 코포레이션 | Acyclic pyrazole compounds |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| BRPI0607006B1 (en) | 2005-02-04 | 2017-05-16 | Senomyx Inc | compounds comprising organic functions of bound heteroaryls and their uses as novel umami flavor modifiers, flavorers and promoters for edible compositions |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CN101687869A (en) | 2007-07-16 | 2010-03-31 | 诺瓦提斯公司 | Tetracyclic lactam derivatives as the MK2 inhibitor |
| AU2008317057B8 (en) | 2007-10-22 | 2014-02-13 | Merck Sharp & Dohme Corp. | Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| MX357627B (en) | 2008-06-27 | 2018-07-17 | Avila Therapeutics Inc | Heteroaryl compounds and uses thereof. |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20110269744A1 (en) * | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| ES2742261T3 (en) * | 2011-04-15 | 2020-02-13 | Hivih | Inhibitors of viral replication, its preparation process and its therapeutic uses |
| WO2013124040A1 (en) | 2012-02-22 | 2013-08-29 | Merck Patent Gmbh | Liquid crystalline medium |
| WO2013146963A1 (en) * | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | Heterocyclic compound |
| TW201406758A (en) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | Tricyclic compounds |
| WO2014011902A1 (en) * | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| AU2013319774A1 (en) * | 2012-09-24 | 2015-05-14 | Claremont SPEEDE | Mobile sender controlled data access and data deletion method and system |
| WO2014050779A1 (en) * | 2012-09-25 | 2014-04-03 | 第一三共株式会社 | Combination of gsk3 inhibitor and anti-dr5 antibody |
| CA2908098A1 (en) * | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015050957A2 (en) | 2013-10-02 | 2015-04-09 | Treatments For Systemic Lupus Erythematosus | Treatments for systemic lupus erythematosus |
| US10512651B2 (en) | 2014-08-25 | 2019-12-24 | Stc.Unm | Inhibition of MK2 in the treatment of cancer |
| RS62017B1 (en) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| CN107406489A (en) | 2015-01-08 | 2017-11-28 | 莫伊莱麦屈克斯公司 | The preparation of MK2 inhibitor peptides |
| JP2020514361A (en) | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | 9,10,11,12-Tetrahydro-8H- [1,4] diazepino [5 ', 6': 4,5] thieno [3,2-F] quinolin-8-one compounds and uses thereof |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2018170201A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Deuterated analogs of mk2 inhibitors and uses thereof |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| EP3969456A4 (en) | 2019-05-17 | 2023-01-25 | Celgene CAR LLC | Methods of treating a mk2-mediated disorder |
| WO2022020562A1 (en) | 2020-07-24 | 2022-01-27 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
-
2015
- 2015-09-16 RS RS20210725A patent/RS62017B1/en unknown
- 2015-09-16 EA EA201790380A patent/EA037299B1/en not_active IP Right Cessation
- 2015-09-16 PT PT158429035T patent/PT3193611T/en unknown
- 2015-09-16 BR BR112017005266-0A patent/BR112017005266B1/en active IP Right Grant
- 2015-09-16 MA MA40534A patent/MA40534B1/en unknown
- 2015-09-16 SI SI201531617T patent/SI3193611T1/en unknown
- 2015-09-16 ES ES15842903T patent/ES2874561T3/en active Active
- 2015-09-16 WO PCT/US2015/050495 patent/WO2016044463A2/en active Application Filing
- 2015-09-16 KR KR1020177010439A patent/KR102457848B1/en active Active
- 2015-09-16 AU AU2015317741A patent/AU2015317741B2/en active Active
- 2015-09-16 DK DK15842903.5T patent/DK3193611T3/en active
- 2015-09-16 SG SG10201902326XA patent/SG10201902326XA/en unknown
- 2015-09-16 HU HUE15842903A patent/HUE054347T2/en unknown
- 2015-09-16 SM SM20210311T patent/SMT202100311T1/en unknown
- 2015-09-16 SG SG11201701861RA patent/SG11201701861RA/en unknown
- 2015-09-16 EP EP15842903.5A patent/EP3193611B1/en active Active
- 2015-09-16 HR HRP20210529TT patent/HRP20210529T1/en unknown
- 2015-09-16 US US14/856,311 patent/US9458175B2/en active Active
- 2015-09-16 EP EP21164056.0A patent/EP3912981A1/en active Pending
- 2015-09-16 CN CN201580058026.4A patent/CN106998692B/en active Active
- 2015-09-16 CA CA2961607A patent/CA2961607C/en active Active
- 2015-09-16 PL PL15842903T patent/PL3193611T3/en unknown
- 2015-09-16 JP JP2017515845A patent/JP6556225B2/en active Active
- 2015-09-16 LT LTEP15842903.5T patent/LT3193611T/en unknown
- 2015-09-16 MX MX2017003359A patent/MX373341B/en active IP Right Grant
- 2015-09-16 TW TW104130645A patent/TWI744217B/en active
-
2016
- 2016-09-29 US US15/280,157 patent/US9790235B2/en active Active
-
2017
- 2017-03-09 IL IL25105117A patent/IL251051B/en active IP Right Grant
- 2017-03-09 CL CL2017000576A patent/CL2017000576A1/en unknown
- 2017-03-14 MX MX2020005213A patent/MX2020005213A/en unknown
- 2017-03-16 SA SA517381115A patent/SA517381115B1/en unknown
- 2017-04-04 CO CONC2017/0003279A patent/CO2017003279A2/en unknown
- 2017-04-13 EC ECIEPI201723281A patent/ECSP17023281A/en unknown
- 2017-10-13 US US15/782,995 patent/US10253040B1/en active Active
-
2019
- 2019-04-04 US US16/375,317 patent/US10577380B2/en active Active
- 2019-07-09 JP JP2019127476A patent/JP2019194236A/en active Pending
-
2020
- 2020-02-27 US US16/802,654 patent/US11584757B2/en active Active
-
2021
- 2021-06-09 CY CY20211100504T patent/CY1124215T1/en unknown
-
2022
- 2022-03-16 JP JP2022041396A patent/JP7375072B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005213A (en) | Mk2 inhibitors and uses thereof. | |
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| MX2015008999A (en) | Mk2 inhibitors and uses thereof. | |
| MX2016003843A (en) | Irak inhibitors and uses thereof. | |
| PH12018501159A1 (en) | Composition and methods for immunooncology | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| MX2018016038A (en) | Compounds and methods for modulating rna function. | |
| NZ740590A (en) | Htt repressors and uses thereof | |
| HK1216859A1 (en) | Irak inhibitors and uses thereof | |
| MX2018009773A (en) | Heteroaryl inhibitors of pad4. | |
| MY191581A (en) | Anti-pd-1 antibodies | |
| MX2017003478A (en) | Anti-fgfr2/3 antibodies and methods using same. | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| MX2018006632A (en) | Bicyclic inhibitors of pad4. | |
| MX2018001890A (en) | Bicyclic compounds as atx inhibitors. | |
| MX2018004674A (en) | Modulators of sestrin-gator2 interaction and uses thereof. | |
| HK1217410A1 (en) | Erk inhibitors and uses thereof | |
| MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
| MX2020001793A (en) | Ahr inhibitors and uses thereof. | |
| NZ725917A (en) | Novel polymerase-i inhibitors, uses and methods for making them | |
| MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
| MX2020001756A (en) | Benzoquinolone inhibitors of vmat2. | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| PH12017501022A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |